title: Efficacy and safety of ormeloxifene in management of menorrhagia: a pilot study.
abstract: OBJECTIVE
  To assess the efficacy and safety of ormeloxifene (centchroman) in the medical management of menorrhagia.
  
  
  METHODS
  Forty-two women with menorrhagia were recruited for the study. Ormeloxifene was given to each patient 60 mg twice a week for 3 months and then once a week for 1 month. Patients were followed up at 2 and 4 months of therapy, then at 3 and 6 months after treatment was stopped. Menstrual blood loss (MBL) was measured objectively by a pictorial blood loss assessment chart (PBAC) score and subjectively by a visual analog scale (VAS).
  
  
  RESULTS
  The pretreatment median PBAC score was 388 (range 169-835). Eighteen patients (42.9%) had amenorrhea with the therapy. Median PBAC reduced to 80 (range 0-730) and 5 (range 0-310) at 2 and 4 months, respectively (P-value <0.001); thus, the percentage reduction was 97.7% at 4 months. Seven patients (16.7%) had no response and three (7.1%) discontinued treatment before 4 months. During the 10-month study period, 21% of the patients underwent hysterectomy. Adverse effects included ovarian cyst (7.1%), cervical erosion and discharge (7.1%), gastric dyspepsia (4.8%), vague abdominal pain (4.8%) and headache (4.8%).
  
  
  CONCLUSIONS
  Ormeloxifene is an effective and safe therapeutic option for the medical management of menorrhagia.
authors.affiliation: Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India. kriplanialka@hotmail.com
authors.forename: Alka
authors.initials: A
authors.lastname: Kriplani
authors.forename: Vidushi
authors.initials: V
authors.lastname: Kulshrestha
authors.forename: Nutan
authors.initials: N
authors.lastname: Agarwal
mesh_terms: D000328:Adult; D001578:Benzopyrans / Q000009:adverse effects / Q000627:therapeutic use*; D004717:Endometrium / Q000473:pathology; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D055118:Medication Adherence; D008595:Menorrhagia / Q000188:drug therapy* / Q000473:pathology; D010865:Pilot Projects; D012008:Recurrence; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D001578:Benzopyrans; D006454:Hemoglobins; D020845:Selective Estrogen Receptor Modulators; C508548:ormeloxifene